SCHEMBL4549005

SCHEMBL4549005

COc1cc2nccc(Oc3ccc4c(C(=O)Nc5cc(C)on5)cccc4c3F)c2cc1OC

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 17/20 0.73
CYP3A4 P08684 3/20 0.55
LCK P06239 3/20 0.53
MET P08581 3/20 0.53
TEK Q02763 3/20 0.53
AURKB Q96GD4 3/20 0.53
FLT1 P17948 2/20 0.53
FLT4 P35916 2/20 0.53
FLT3 P36888 2/20 0.53
RIPK2 O43353 1/20 0.53
STK10 O94804 1/20 0.53
ABL1 P00519 1/20 0.53
LYN P07948 1/20 0.53
RET P07949 1/20 0.53
PDGFRB P09619 1/20 0.53
KIT P10721 1/20 0.53
BCR P11274 1/20 0.53
FGFR1 P11362 1/20 0.53
SRC P12931 1/20 0.53
PDGFRA P16234 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4548745 0.89 KDR (0.73) KDRCYP3A4FLT3
SCHEMBL2748593 0.89 KDR (0.74) KDRCYP3A4LCKMETTEK
SCHEMBL4549000 0.85 KDR (0.85) KDRCYP3A4LCKMETTEK
SCHEMBL2747336 0.85 KDR (0.85) KDRCYP3A4LCKMETTEK
SCHEMBL2747740 0.85 KDR (0.75) KDRCYP3A4LCKMETTEK
SCHEMBL4549004 0.84 KDR (0.78) KDRCYP3A4LCKMETTEK
SCHEMBL4549006 0.84 KDR (1.00) KDRCYP3A4LCKMETTEK
SCHEMBL4549002 0.84 KDR (0.87) KDRCYP3A4LCKMETTEK
SCHEMBL2747089 0.84 KDR (1.00) KDRCYP3A4LCKMETTEK
SCHEMBL4549001 0.83 KDR (0.79) KDRCYP3A4LCKMETTEK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 US disclosed
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176774-A1 Compounds and methods of use HGF, HGFAC, MET KDR 354/4885CYP3A4 348/4885LCK 1106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.